Trevena, Inc. (TRVN) Reaches $1.63 1 Year Low; Scotia Capital Lowered Its Gildan Activewear (GIL) Holding

February 11, 2018 - By Linda Rogers

Scotia Capital Inc decreased Gildan Activewear Inc (GIL) stake by 8.26% reported in 2017Q3 SEC filing. Scotia Capital Inc sold 13,459 shares as Gildan Activewear Inc (GIL)’s stock rose 10.95%. The Scotia Capital Inc holds 149,436 shares with $4.67M value, down from 162,895 last quarter. Gildan Activewear Inc now has $6.67B valuation. The stock decreased 1.53% or $0.48 during the last trading session, reaching $30.83. About 668,139 shares traded or 76.58% up from the average. Gildan Activewear Inc. (NYSE:GIL) has declined 3.41% since February 11, 2017 and is downtrending. It has underperformed by 20.11% the S&P500.

The stock of Trevena, Inc. (NASDAQ:TRVN) hit a new 52-week low and has $1.55 target or 5.00% below today’s $1.63 share price. The 9 months bearish chart indicates high risk for the $101.55M company. The 1-year low was reported on Feb, 11 by Barchart.com. If the $1.55 price target is reached, the company will be worth $5.08M less. The stock increased 7.95% or $0.12 during the last trading session, reaching $1.63. About 1.80M shares traded or 112.43% up from the average. Trevena, Inc. (NASDAQ:TRVN) has declined 52.53% since February 11, 2017 and is downtrending. It has underperformed by 69.23% the S&P500.

Scotia Capital Inc increased Fedex Corp (NYSE:FDX) stake by 28,398 shares to 88,795 valued at $20.02 million in 2017Q3. It also upped Ishares Tr (TIP) stake by 13,665 shares and now owns 30,189 shares. Hudbay Minerals Inc (NYSE:HBM) was raised too.

Analysts await Gildan Activewear Inc. (NYSE:GIL) to report earnings on February, 22. They expect $0.31 EPS, down 3.13% or $0.01 from last year’s $0.32 per share. GIL’s profit will be $67.10M for 24.86 P/E if the $0.31 EPS becomes a reality. After $0.53 actual EPS reported by Gildan Activewear Inc. for the previous quarter, Wall Street now forecasts -41.51% negative EPS growth.

Among 14 analysts covering Gildan Activewear Inc. (NYSE:GIL), 7 have Buy rating, 0 Sell and 7 Hold. Therefore 50% are positive. Gildan Activewear Inc. had 34 analyst reports since August 4, 2015 according to SRatingsIntel. RBC Capital Markets maintained the stock with “Hold” rating in Friday, November 3 report. The firm earned “Sell” rating on Monday, August 17 by Zacks. The firm earned “Outperform” rating on Tuesday, August 4 by Scotia Capital. The firm has “Buy” rating by BMO Capital Markets given on Thursday, August 3. RBC Capital Markets maintained the stock with “Hold” rating in Tuesday, September 26 report. The firm has “Buy” rating given on Thursday, November 2 by GMP Securities. RBC Capital Markets maintained the stock with “Outperform” rating in Friday, November 13 report. Stifel Nicolaus maintained it with “Buy” rating and $32 target in Thursday, February 25 report. On Tuesday, August 4 the stock rating was downgraded by Credit Suisse to “Neutral”. The firm has “Sector Perform” rating given on Friday, August 4 by National Bank Canada.

Trevena, Inc., a biopharmaceutical company, develops various therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The company has market cap of $101.55 million. The Company’s product candidates include oliceridine injection, a µ-receptor G protein pathway selective modulator, which is in Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in preclinical development for the treatment of migraine; and TRV734, a small molecule G protein biased ligand at the mu-receptor that is in Phase I clinical trials for the treatment of moderate to severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure. It currently has negative earnings.

Analysts await Trevena, Inc. (NASDAQ:TRVN) to report earnings on March, 14. They expect $-0.26 EPS, up 61.19% or $0.41 from last year’s $-0.67 per share. After $-0.27 actual EPS reported by Trevena, Inc. for the previous quarter, Wall Street now forecasts -3.70% EPS growth.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>